Bio Innovation is
We are developing several biological products for the treatment of unmet needs diseases such as the “diabetic foot infections” and other conditions.
Our goal is to improve the quality of life of all individuals across the globe.
At Lxbio Pharmaceuticals, we are committed to discover biopharmaceutical solutions that aim to transform healthcare and improve patient health outcomes. Our portfolio encompasses a range of innovative therapies developed through advanced biotechnological processes.
Welcome to Lxbio, where the future of biopharmaceuticals is being redefined. As a newly established pharmaceutical company, we present a compelling opportunity for investors seeking to be at the forefront of groundbreaking innovation in the global biopharmaceutical market.
Invest with us
The Business Year Portugal 2023 was recently launched.
In this edition, Miguel Garcia, CEO of Lxbio, had the pleasure of granting an interview where he presents our company, explains the goals and the role that LxBio intends to play in the Portuguese and international market.
Last month TechnoPhage, founding partner and shareholder of Lxbio, attended ECCMID 2023. Together with the clinical team from Israel, it was presented the results from two cases of compassionate use carried out in Israel, under the supervision of Dra. Michal Deckel.
Lxbio, together with partners Technophage, VectorB2B and FFUL is pleased to announce the signing of a new PRR Grant Agreement with the Portuguese Government, in the scope of the Mobilizing Agendas for Business Innovation in Portugal.